Maxim Group resumed coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.11 on June 5. On May 1, the SEC suspended trading in Moleculin, citing questions about the...
Tag - ImQuest Biosciences
